证券代码：688273 证券简称：麦澜德 公告编号：2025-027 南京麦澜德医疗科技股份有限公司 关于控股股东、实际控制人续签《共同控制协议》及原 《一致行动协议》到期解除、部分股东重新签订《一致 行动协议》暨权益变动的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次权益变动是由于南京麦澜德医疗科技股份有限公司（以下简称"公司" 或"麦澜德"）控股股东、实际控制人杨瑞嘉先生与史志怀先生在公司首次公开发行 股票上市前签署的《共同控制协议》，以及二人与陈彬先生、屠宏林先生、周干 先生、周琴女士签署的原《一致行动协议》到期解除，杨瑞嘉先生与史志怀先生 续签《共同控制协议》，并与陈彬先生、屠宏林先生、周琴女士及王旺先生重新 签订《一致行动协议》所致。由于周干先生未续签《一致行动协议》，与其他股 东的一致行动关系解除，周干先生不再与公司实际控制人构成一致行动关系。本 次权益变动不触及要约收购。 本次权益变动后，公司控股股东、实际控制人杨瑞嘉先生、史志怀先生直 接持股情况不变，与一致行动人的合计直接 ...

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing significant growth driven by favorable government policies and technological advancements, with expectations for substantial market expansion in the coming years [1][4]. Group 1: Market Performance - On August 8, stocks related to the brain-computer interface concept surged, with notable gains including Beiyikang at 13% limit up and Sanbo Brain Science at over 11% [1]. - Other companies such as Innovation Medical and Jihua Group also reached their limit up, indicating strong market interest [1]. Group 2: Government Policies - The Ministry of Industry and Information Technology, along with six other departments, issued implementation opinions aimed at promoting innovation in the BCI industry, targeting breakthroughs in key technologies by 2027 [2]. - By 2030, the goal is to establish a reliable industrial system and cultivate globally influential leading enterprises within the BCI sector [2]. Group 3: Industry Insights - The National Medical Insurance Administration has introduced a pricing mechanism for newly launched drugs and medical devices, facilitating the commercialization of new technologies [3]. - Recent reports indicate that the BCI sector is accelerating its commercial transformation, with non-invasive applications in medical rehabilitation and emotional management gaining traction [4]. - The domestic BCI market is expected to expand rapidly, supported by favorable policies and advancements in technology [4].

Group 1 - The total salary scale of CFOs in A-share listed companies reached 4.27 billion yuan in 2024, with an average annual salary of 814,800 yuan [1] - In the medical device sector, the average annual salary of CFOs is 1.0652 million yuan, with 31% earning below 500,000 yuan, 43% between 500,000 and 1 million yuan, 20% between 1 million and 2 million yuan, and 6% above 2 million yuan [2] - The age distribution of CFOs shows that 54% are aged between 40 and 50, 35% are over 50, and 11% are 40 or younger, with the youngest being 30 years old and the oldest being 65 years old [1] Group 2 - The top three highest-paid CFOs in the medical device sector are Zhao Yun from Mindray Medical with 8.4134 million yuan, Liu Lihua from Yuyue Medical with 4.3136 million yuan, and Jing Xiaoqian from Wandong Medical with 1.6412 million yuan [2] - The CFO with the largest salary decrease in 2024 is Zhang Qiu from Kangtong Medical, with a year-on-year decrease of 31.23%, while Xu Ning from Mcland saw the largest increase at 165.59% [2] - The educational background of CFOs shows that 71% hold a bachelor's degree, 23% a master's degree, and only 3% hold a doctoral degree, with only one CFO having a PhD [1]

医疗器械 ETF（562600）为投资者提供一键把握医疗器械行业成长机遇的便捷工具。该ETF追踪的中证 全指医疗器械指数，精心选取 100 支覆盖医疗器械、医疗服务、医疗信息化等核心医疗领域的代表性上 市公司证券作为样本。按wind脑机接口指数测算，截至2025年8月6日指数含脑机接口权重21.9%，从行 业结构看，该指数医疗器械行业占比高达 89.08%，集中度突出，能精准捕捉医疗器械领域的发展红 利。感兴趣的投资者可以持续关注。 （文章来源：每日经济新闻） 提出到2027年、2030年两步走发展目标，明确五大重点任务，细化17项具体举措，进一步推动脑机接口 产业高质量发展。这一重磅文件的出台，为我国脑机接口产业的未来发展描绘了清晰的蓝图，有望在全 球科技竞争中抢占先机，培育出具有国际竞争力的未来产业新赛道。 受此影响，医疗器械板块持续活跃，医疗器械ETF短暂调整后直线拉升，发稿时涨超1%。持仓股票赛 诺医疗20厘米涨停，利德曼、麦澜德、尚荣医疗、美好医疗涨幅居前。 消息面，工业和信息化部、国家发展改革委等7 部门发布关于推动脑机接口产业创新发展的实施意见。 ...

Group 1 - The assisted reproductive industry is experiencing a rebound, with significant stock price increases for several companies [1] - Lideman's stock rose over 18%, indicating strong market interest and potential recovery in the sector [1] - Other companies such as Nanmo Bio, Mailande, and Guangshengtang also saw notable gains, with increases of over 15%, 14%, and additional follow-up gains from other firms [1]

Group 1 - The core viewpoint of the news is the significant advancements expected in brain-computer interface (BCI) technology by 2027, with the establishment of an advanced technical, industrial, and standard system [1][3] - The Ministry of Industry and Information Technology, along with six other departments, has issued implementation opinions to promote innovation and development in the BCI industry, aiming for breakthroughs in key technologies and the establishment of a robust industrial ecosystem by 2030 [3] - The BCI market is projected to expand rapidly, driven by the increasing application of BCI products in various sectors such as industrial manufacturing, healthcare, and consumer life [3][4] Group 2 - Following positive news, several BCI-related stocks experienced significant price increases, with Beiyikang reaching a 13.57% rise and Sanbo Brain Science increasing by 11.69% [2] - The report from Founder Securities highlights the acceleration of commercial transformation in the BCI sector, particularly in non-invasive applications for medical rehabilitation and emotional management, indicating a broad market outlook [4] - Open Source Securities notes that the BCI technology landscape is undergoing rapid transformation, with upstream technological advancements leading to breakthroughs in downstream applications, suggesting a promising commercial future for domestic BCI companies [4]

Core Viewpoint - The company has approved the use of up to RMB 52,600 million of temporarily idle raised funds for cash management, ensuring that this does not affect the implementation of fundraising investment projects and is in the interest of all shareholders [3][22]. Group 1: Meeting Details - The second meeting of the supervisory board was convened on July 25, 2025, via communication, with all three supervisors present, complying with relevant laws and regulations [2]. - The meeting's resolutions were deemed legal and effective [2]. Group 2: Fund Management Proposal - The supervisory board approved the proposal to use up to RMB 52,600 million of temporarily idle raised funds for cash management, which aligns with regulatory requirements and does not conflict with the intended use of the raised funds [3][22]. - The funds will be invested in low-risk, high-liquidity products such as structured deposits, large certificates of deposit, and time deposits, with a usage period of 12 months from the approval date [7][11]. Group 3: Fundraising Overview - The company raised a total of RMB 100,725 million through its initial public offering, with a net amount of RMB 90,975.85 million after deducting issuance costs [7][8]. - All raised funds are stored in a dedicated account, and the company has established a three-party supervision agreement with the underwriter and the bank [8]. Group 4: Investment Purpose and Benefits - The purpose of using idle funds for cash management is to enhance fund utilization efficiency and increase returns while ensuring the safety of the raised funds [10]. - This strategy is expected to improve overall performance and provide better returns for shareholders [17]. Group 5: Approval and Oversight - The proposal received unanimous approval from the supervisory board, confirming that it complies with relevant regulations and does not harm shareholder interests [22][23]. - The underwriter has also expressed no objections to the cash management plan, affirming that it will not affect the company's main business operations [24].

Group 1 - The company held its 12th meeting of the second Supervisory Board on July 25, 2025, via communication, with all three supervisors present, ensuring compliance with relevant laws and regulations [1][2] - The Supervisory Board approved the proposal to use up to RMB 526 million of temporarily idle raised funds for cash management, stating that this decision aligns with regulatory requirements and does not conflict with the implementation of investment projects [1][2] - The decision to manage idle funds is expected to enhance the company's capital efficiency and yield good financial returns, with unanimous support from all supervisors [1]

南京证券股份有限公司 使用部分暂时闲置募集资金进行现金管理的核查意见 南京证券股份有限公司（以下简称"南京证券"或"保荐机构"）作为麦澜 德医疗科技股份有限公司（以下简称"麦澜德"或"公司"）首次公开发行股票 并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上市公 司募集资金监管规则》《上海证券交易所科创板股票上市规则》《上海证券交易 所科创板上市公司自律监管指引第 1 号——规范运作》等法律法规和规范性文件 的要求，对麦澜德使用部分暂时闲置募集资金进行现金管理的事项进行了认真、 审慎的核查，核查情况如下： 一、本次募集资金基本情况 根据中国证券监督管理委员会（以下简称"中国证监会"）出具的《关于同 意南京麦澜德医疗科技股份有限公司首次公开发行股票注册的批复》（证监许可 〔2022〕1189 号），公司获准向社会公众公开发行人民币普通股（A 股）2,500 万 股，每股面值为人民币 1 元，每股发行价格为人民币 40.29 元，募集资金总额为人 民币 100,725.00 万元，扣除各项发行费用人民币 9,749.15 万元（不含增值税）后， 实际募集资金净额为人民币 90,975.85 万元 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688273 证券简称：麦澜德 公告编号：2025-026 南京麦澜德医疗科技股份有限公司 关于使用部分暂时闲置募集资金进行现金管理的公告 | 序号 | 项目名称 | 项目总投资额 （万元） | 拟投入募集资金额 （万元） | 自有资金投入 （万元） | | --- | --- | --- | --- | --- | | 1 | 麦澜德总部生产基地建 设项目 | 38,505.80 | 36,919.00 | 1,586.80 | | 2 | 研发中心建设项目 | 21,203.07 | 15,167.33 | 6,035.74 | | 3 | 营销服务及信息化建设 项目 | 5,291.61 | 5,291.61 | 0.00 | | | 合计 | 65,000.48 | 57,377.94 | 7,622.54 | 截至 2024 年 12 月 31 日，公司募投项目及募集资金使用情况具体详见公司于 2025 年 4 月 24 日披露于上海证券交易所网站（www ...